Security key
74365N301
Protagenic Therapeutics, Inc.\new - COM (PTIX)
CUSIP: 74365N301
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / COM
- Total 13F shares
- 116,479
- Total 13F value
- $150,922
- Share change
- +16,068
- SEC-reported price per share
- $1.30
- Number of holders
- 11
- Value change
- -$39,581
- Number of buys
- 8
- Number of sells
- 4
Report period
Q4 2025
Institutions
11
Top holders
10
PTIX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Protagenic Therapeutics, Inc.\new SEC filings
Protagenic Therapeutics, Inc.\new company facts
Broader feeds
Reporting periods
Holder history for CUSIP 74365N301
Recent filing periods:
Ownership snapshot
Top reported holders of PTIX - Protagenic Therapeutics, Inc.\new - COM (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
Garo H. Armen
Comparable rows
1/15
Latest evidence
30 Sep 2025
13D/G
3/4/5
13F
Lead comparable stake: 3.4%
14 rows are not safely comparable across share classes.
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-6 of 15 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 3.4%.
1 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 1
ARMISTICE CAPITAL, LLC
3.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
|
3.4%
|
$52,800
240,000 shares
|
$0 | 31 Dec 2024 |
| Garo H. Armen |
3/4/5
Executive Chairman, Director, 10%+ Owner
|
—
class O/S missing
|
$435,000
250,000 shares
|
— | 25 Mar 2024 |
| Barrett Evans |
3/4/5
ex CEO, Director, 10%+ Owner
|
—
mixed-class rows
|
$67,204
154,552 shares
mixed-class rows
|
— | 15 May 2025 |
| Alexander K. Arrow |
3/4/5
Chief Financial Officer
|
—
mixed-class rows
|
$211,110
145,815 shares
mixed-class rows
|
— | 25 Mar 2024 |
| Jennifer Buell |
3/4/5
Director
|
—
class O/S missing
|
$130,500
75,000 shares
|
— | 25 Mar 2024 |
| Stein Robert Benjamin |
3/4/5
Director
|
—
class O/S missing
|
$130,500
75,000 shares
|
— | 25 Mar 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
11
Shares
116,479
Rows available
11
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
10
Q4 2025 holders
11
Holder diff
1
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend